INTELLIGENCE: SEVEN POTENTIAL BIOTECH BUYOUT TARGETS IN WAKE OF ARIAD BUYOUT $ARIA $BMRN $EXEL $FOLD $INCY $MDVN $RARE $SGEN $TSRO

INTELLIGENCE: SEVEN POTENTIAL BIOTECH BUYOUT TARGETS IN WAKE OF ARIAD BUYOUT $ARIA $BMRN $EXEL $FOLD $INCY $MDVN $RARE $SGEN $TSRO

This post was just published on ZYX Buy Change Alert.

For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens. Our rigorous criteria has led to enviable performance over a long period of time. We periodically provide intelligence on trades that we do not recommend, but our subscribers may be able to take advantage.

Previously our subscribers benefited handsomely from buyout of MDVN.  MDVN was long from $55.50 and the stock was tendered at $81.50 producing an annualized return of 149%.  In the wake of MDVN buyout, we published a post INTELLIGENCE: EIGHT POTENTIAL BUYOUT TARGETS IN THE WAKE OF MDVN BUYOUT .

ARIA was on the top of that list and now it has produced 237% gain for some of our subscribers.  The following seven stocks still remain prime buyout targets.

BMRN

EXEL

FOLD

INCY

RARE

SGEN

TSRO

All of these seven companies that are not in the portfolio are on our radar.  We are likely to issue official buy signals with buy zones, target zones and stop zones in due course when our strict criteria is met.

In the interim, in response to the last post, some of our sophisticated subscribers already purchased a basket of these stocks.  Sophisticated subscribers who are aggressive may consider purchasing a basket of these seven stocks with small quantities on pullbacks as our stringent criteria to give official signals may not be met.

Trades posted on The Arora Report Market Blog have produced unrivalled performance since 2007.  Please click here and scroll down to see the table of all trades.  These trades have been scrutinized in real-time by thousands of subscribers across the globe.  This provides easy verification of performance for newcomers to this site.  Only those trades are included in the performance where the entry post was made available to subscribers to The Arora Report Market Blog.  When the entry post is made available only to the paying subscribers and not posted in real-time on The Arora Report Market Blog, the resulting performance of the trade is not credited in the performance table.  There are very nice gains on these trades but since the entry trade was not posted here in real-time, handsome profits on these trades will not be added to the performance of The Arora Report Market Blog shown on the table.

You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES.

Please click here to take advantage of a FREE  30 day trial.

Check out our enviable performance in both bull and bear markets.

FREE: SUBSCRIBE TO ‘GENERATE WEALTH’ NEWSLETTER

Related Posts

OUR POSITION ARIAD PHARMA GETS $24 BUYOUT OFFER, 237% RETURN FOR OUR SUBSCRIBERS $ARIA $ALIOY $TKPYY

This post was published on ZYX Buy Change Alert.  Original ARIA position is long from $7.11.  The buyout price represents 237% return.  If ...

OBAMACARE IS DEAD, WELCOME TRUMPCARE OPPORTUNITIES! $SPY $XLV $XHS $PJP $XBI $IHI $BMY $JNJ $PFE $MRK $ABT $ABBV $LLY $HUM $UNH $AET $ANTH $CI $HCE $CVH $THC $CNC $MOH

Democrats will fight tooth and nail to save Obamacare, but given the flaws in the plan, they are not likely ...

INTELLIGENCE: EIGHT POTENTIAL BUYOUT TARGETS IN THE WAKE OF MEDIVATION BUYOUT $ARIA $BMRN $EXEL $FOLD $INCY $RARE $SGEN $TSRO $MDVN $PFE

This post was just published on ZYX Buy Change Alert. For us to recommend, a stock must pass at least four of ...

THE ARORA REPORT SUBSCRIBERS MAKE 143% ANNUALIZED RETURN ON MEDIVATION BUYOUT BY PFIZER $MDVN $PFE

This post was just published on ZYX Buy Change Alert. MDVN is the 113th company in our portfolio involved in M&A.  The Arora ...

GET AHEAD OF SUPREME COURT ON OBAMACARE, TAKE PROFITS AND REVIEW HEALTHCARE POSITIONS $CYH $THC $RAD $WBA $MOH $CNC $PRGO $MYL #OBAMACARE

This post was just published on ZYX Buy Change Alert. The Supreme Court is likely to make a ruling on Obamacare this ...

TAKE PROFITS ON ARIAD $ARIA

This post was just published on ZYX Buy Change Alert. Consider taking profits on ARIA or protecting them with a closer trailing ...

RAISE THE STOP ON ARIAD $ARIA

This post was just published on ZYX Buy Change Alert. Consider raising the stop on ARIA to break even.

A NEW IDEA ON ARIAD $ARIA

This post was just published on ZYX Buy Change Alert. ARIA stock has been decimated as FDA puts a hold on its ...

WE SOLD SHORT DIABETES STOCKS PER EARLIER POST

We are short diabetes stocks with following average sell prices: LLY 35.30, INCY 4.15, ALKS 9.20, AMLN 11.50 and ...

TRADES ON DIABETES STOCKS

Based on our analysis of the presentations at American Diabetes Association's Annual Meeting in New Orleans, we expect the following ...

TIGHTEN STOPS ON CANCER STOCKS

We have profits on both our long and short cancer trades. Our analysis indicates that it is time to ...

CONSIDER LIGHTLY ADDING TO CANCER STOCK SHORTS ON THIS RALLY

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE ...

STATUS OF CANCER STOCKS

Per our earlier post, we are short on OSIP from $32.2, SNTA from $3.50and EXEL from $5.35.We are long on ...

ENCOURAGING DATA AT ASCO

Our review of the data presented at 2009 Annual Meeting of the American Society of Clinical Oncology held in Orlando ...

Follow

Get every new post delivered to your Inbox

Join other followers

make money

327 WINNING TRADES

21 LOSING TRADES

1090.62% ANNUALIZED AVERAGE RETURN PER TRADE
Easily Verifiable

CLICK HERE TO

CHECK OUT FREE TRIALS

START GENERATING WEALTH NOW!

FREE: SUBSCRIBE TO ‘GENERATE WEALTH’ NEWSLETTER